## HHP Care Model and Disease Management Webinar Series

#### **Skin Cancer: Who What When How?**

### Thursday, June 10, 2021 5:30pm – 6:30pm

#### HAWAI'I PACIFIC HEALTH

HAWAI'I HEALTH PARTNERS



#### Moderator - 06/10/21

#### Andy Lee, MD

Medical Director, *Hawai'i Health Partners* Chief of Staff, *Pali Momi Medical Center* Hawai'i Pacific Health

#### HAWAI'I PACIFIC HEALTH

2

HAWAI'I

HEALTH

PARTNERS

### **Disclaimer:**

- The following is intended as information resource only for HHP/HPH providers, clinicians, administrative and clinical leaders.
- Specific areas may not pertain directly to your clinical practice area and/or may not be applicable to your practice based on your existing workflows, infrastructure, software (e.g. EHR), and communications processes.

## **Webinar Information**

- You have been automatically muted. You cannot unmute yourself.
- You will be able to submit questions via the Q&A section.
  - Due to time constraints, any unanswered questions will be addressed this week and posted on the HHP website
- A recording of the meeting will be available on the HHP website and intranet.

### How to Claim CME Credit

#### 1. Step 1: Confirm your attendance

 You should have completed a brief questionnaire before joining today's live webinar.

#### 2. Step 2: HPH CME team will email you instructions

- Complete and submit evaluation survey that will be emailed to you within one week of the offering.
- Your CE certificate will be immediately available to you upon completion of your evaluation.
- Questions? Email
  <u>hphcontinuingeduc@hawaiipacifichealth.org</u>



### **CME Accreditation Statement**

- In support of improving patient care, Hawai'i Pacific Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
- Hawai'i Pacific Health designates this webinar activity for a maximum of 1.0 AMA PRA Category 1 Credit (s) ™ for physicians. This activity is assigned 1.0 contact hour for attendance at the entire CE session.



#### JOINTLY ACCREDITED PROVIDER™

INTERPROFESSIONAL CONTINUING EDUCATION




#### Disclosures

 The planners and presenters of this activity report no relationships with companies whose products or services (may) pertain to the subject matter of this meeting

7

# Skin Cancer: Who, What, When and How



Iris Noh, MD Dermatology, Straub Medical Center, Hawai'i Pacific Health



Elizabeth LoGalbo, DO

Primary Care Physician - Family Medicine, Straub Lana'i Family Health Center, Hawai'i Pacific Health



**Robert Schulz, MD** 

Chief of Plastic Surgery, Hawaiʻi Pacific Health Medical Group, Straub Medical Center

Director, Straub Burn Center

#### HAWAI'I PACIFIC HEALTH

HAWAI'I HEALTH PARTNERS

## **Objectives**

- WHO?
  - Who is at risk?
- WHAT?
  - What are the types of skin cancers?
- WHEN?
  - When should patients be referred to a dermatologist?
- HOW?
  - How can we prevent skin cancer?
- 1. Name phenotypic and environmental risk factors for common skin cancers
- 2. Recognize typical clinical presentations of common skin cancers



## WHY?

#### Why does skin cancer matter?

#### HAWAI'I PACIFIC HEALTH

HAWAI'I HEALTH PARTNERS

#### Skin cancer is the most common cancer in the United States

- 1 in 5 Americans will develop skin cancer in their lifetime
  - Over 95% of which will be Nonmelanoma Skin Cancer (NMSC)
- Increasing incidence in US
- Annual US cost estimated at \$8.1 billion
- In women age 15-29, melanoma is the most common cancer

#### Rogers HW, et al. JAMA Dermatol. 2015;151(10):1081-6,

Guy GP, Machlin SR, Ekwueme DU, Yabroff KR. Prevalence and costs of skin cancer treatment in the US, 2002-2006 and 2007-2011. Guy GP, Thomas CC, Thompson T, Watson M, Massetti GM, Richardson LC. Vital signs: Melanoma incidence and mortality trends and projections—United States, 1982–2030. MMWR Morb Mortal Wkly Rep. 2015;64(21):591-596






Figure 3. Age-Adjusted Melanoma Incidence Rates, Actual and Projected, by Sex, 1975-2020

····· MALE — FEMALE

#### Note: Data after vertical dotted line are projected rates

Source: Surveillance, Epidemiology, and End Results (SEER) Program, National Cancer institute (http://www.seer.cancer.gov). SEER 9 incidence Database (1973–2010). November 2011 submission. Nordpred software used to create age-period-cohort regression models to calculate projections.

## WHAT

#### What are common types of skin cancer?

#### HAWAI'I PACIFIC HEALTH PARTNERS


12


## **Skin Cancer Types**

- Non-melanoma skin cancer
  - Basal cell carcinoma (BCC)
  - Squamous cell carcinoma (SCC)
- Melanoma
- Merkel cell carcinoma
- Sebaceous carcinoma
- Atypical fibroxanthoma (AFX)
- Dermatofibrosarcoma protuberans (DFSP)
- Extramammary Paget disease (EMPD)
- Microcystic adnexal carcinoma (MAC)
- Cutaneous Leiomyosarcoma
- Porocarcinoma
- Pilomatrical carcinoma, etc.

## Nonmelanoma Skin Cancers (NMSC)

- Also known as Keratinocyte skin cancers
  - Basal cell skin cancer (BCC)
  - Squamous cell skin cancer (SCC)
- Incidence is increasing in people younger than 50
- The ratio of BCC to SCC treated in Medicare beneficiaries is 1:1





BCC indicates basal cell carcinoma; NMSC, nonmelanoma skin cancer; SCC, squamous cell carcinoma. Unspecified NMSCs were not coded as either BCC or SCC.

Rogers HW, Incidence Estimate of NMSC in the US population 2021. JAMA Dermatol 2015:151(1) 1081-1086



## Basal Cell Carcinoma (BCC)

- Most commonly occurs on the head and neck region
- Pearly telangiectatic papule or pink macule with rolled borders
  - "rodent bite"
  - sometimes ulcerated or bleed easily









#### CREATING A HEALTHIER HAWAI'I

PARTNERS

### **Basal Cell Carcinoma**

 Almost never metastasize but are locally destructive






### **Pigmented BCC**









Images from Bolognia, Dermatology, Third Edition, Chapter 108 Actinic Keratosis, Basal Cell carcinoma, and Squamous Cell Carcinoma



## Squamous Cell Carcinoma (SCC)

- May arise from actinic keratosis
- Most commonly occurs on the head, neck, and dorsal hands
- Higher risk of metastasis than BCC
  - 1-4% metastasize
  - 2% die from the disease
    - More deaths than melanoma?
- Clinical presentation may vary
  - In situ
  - Invasive





18

### **Actinic Keratosis**

- Considered precancerous
- Small fraction may evolve into SCC







Images from Bolognia, Dermatology, Third Edition, Chapter 108 Actinic Keratosis, Basal Cell carcinoma, and Squamous Cell Carcinoma

#### HAWAI'I HAWAI'I PACIFIC HEALTH HEALTH PARTNERS

## Squamous Cell Carcinoma in Situ

- Also known as Bowen's disease
- Thin, scaly, erythematous plaque

Limited to the epidermis



Images from Bolognia, Dermatology, Third Edition, Chapter 108 Actinic Keratosis, Basal Cell carcinoma, and Squamous Cell Carcinoma




#### Invasive Squamous Cell Carcinoma (SCC)

 Can exhibit rapid growth

• Tender





 Keratoacanthoma variant can involute

Images from Bolognia, Dermatology, Third Edition, Chapter 108 Actinic Keratosis, Basal Cell carcinoma, and Squamous Cell Carcinoma



## Staging Squamous Cell Carcinoma

#### • Brigham and Women's Hospital SCC Risk Factors:

- Tumor diameter ≥2cm
- Poorly differentiated histology
- Perineural invasion ≥0.1mm
- Tumor invasion beyond fat

Table 1. Summary of the AJCC, UICC, and BWH Tumor (T) Staging Systems Tumor Staging System Definition AJCC T1 Tumor ≤ 2 cm in greatest dimension with fewer than two high-risk factors\* T2 Tumor > 2 cm in greatest dimension or with two or more high-risk factors\* T3 Tumor with invasion of orbit, maxilla, mandible, or temporal bones Τ4 Turnor with invasion of other bones or direct perineural invasion of skull base UICC T1 Tumor ≤ 2 cm or less in greatest dimension T2 Tumor > 2 cm in greatest dimension T3 Tumor with invasion of deep structures (eg, muscle, cartilage, bone [excluding axial skeleton], orbit) Τ4 Tumor with invasion of axial skeleton or direct perineural invasion of skull base BWH T1 0 high-risk factors† T<sub>2a</sub> 1 high-risk factor T<sub>2b</sub> 2-3 high-risk factors T3 ≥ 4 high-risk factors or bone invasion

Abbreviations: AJCC, American Joint Committee on Cancer; BWH, Brigham and Women's Hospital; T, tumor stage from TNM staging system; UICC, International Union Against Cancer.

\*AJCC high-risk factors include > 2 mm thickness, Clark level ≥ IV, perineural invasion, primary site ear, primary site non-hair-bearing lip, or poorly differentiated histology, †BWH high-risk factors include tumor diameter ≥ 2 cm, poorly differentiated histology, perineural invasion ≥ 0.1 mm, or tumor invasion beyond fat (excluding bone invasion which automatically upgrades tumor to BWH stage T3).

Karia P Eva;iatopm pf AJJC, IUAC, BWH Tumor Staging for cSCC, J Clin Oncol 2013 32:327-334

#### в Cumulative Incidence of Nodal Metastasis (probability) 0.6 BWH stage T1 BHW stage T2a BHW stage T2b BHW stage T3 0.4 ~ 00 0.2 0 Follow-Up Duration (years) Follow-Up Duration (years) С (probability) 1.0 -Cumulative Incidence of ase-Specific Death (probal 0.8 BWH stage T BHW stage T2a BHW stage T2b 0.6 - BHW stage T3 0.4 0.2 Dise Follow-Up Duration (years)



#### Melanoma

- Melanoma represents a malignant tumor that arises from melanocytes
- Due to its metastatic potential, leads to >75% of skin cancer deaths
- The incidence rates of melanoma have increased over the past four decades by three- to five-fold, whereas mortality rates began to stabilize in the early 1990s
- Melanoma is one of the most common forms of cancer in females age 15-29
- Melanoma also most common on the upper back, legs, head and neck, but it can appear anywhere (ocular, mucosal, nasal, vulvar)
- Melanocytes are everywhere on the skin
- Prognosis varies quite a bit based on staging



#### Superficial Spreading and Nodular Melanoma



Images from Bolognia, Dermatology, Third Edition, Chapter 113; Melanoma





#### Lentigo Maligna Melanoma





Images from Bolognia, Dermatology, Third Edition, Chapter 113; Melanoma



#### **Straub Melanoma examples**




*In situ* and early invasive cutaneous melanoma can be subtle in appearance but dermoscopy has led to an improvement in diagnostic accuracy






## **Melanoma Staging**

Tumor (T)		
Tis (Mis)	Thickness (mm)	Ulceration
T1 T1a T1b	≤ 1.0 <0.8 <0.8 0.8-1.0	Unknown Without With Without
T2	>1.0-2.0	Unknown
T2a	>1.0-2.0	Without
T2b	>1.0-2.0	With
T3	>2.0-4.0	Unknown
T3a	>2.0-4.0	Without
T3b	>2.0-4.0	With
T4	>4.0	Unknown
T4a	>4.0	Without
T4b	>4.0	With



#### FIGURE 1.

Kaplan-Meier Melanoma-Specific Survival Curves According to T Subcategory for Patients With Stage I and II Melanoma From the Eighth Edition International Melanoma Database. Patients with N0 melanoma have been filtered, so that patients with T2 to T4 melanoma were included only if they had negative sentinel lymph nodes, whereas those with T1N0 melanoma were included regardless of whether they underwent sentinel lymph node biopsy.



HAWAI'I

PACIFIC

HEALTH

Gershenwald J Melanoma Staging: Evidence-Based Changes in the AJCC 8<sup>th</sup> Cancer Staging Manual, CA Cancer J Clin. 2017

#### **CREATING A HEALTHIER HAWAI'I**

HAWAP

HEALTH

PARTNERS

### WHEN

#### When is a lesion concerning?

#### HAWAI'I PACIFIC HEALTH

HAWAI'I HEALTH PARTNERS

## A Concerning Lesion

Helpful to know

- 1. Size
- 2. Location and Photo (near and distant)
- 3. Associated symptoms
  - 1. Bleeding or draining
  - 2. Does not heal
  - 3. Rapidly growing
  - 4. Painful

4. Other factors to know such as duration or changes in appearance "quarter-sized painful nodule on the

III appearance quarter-sized paintul nodule on left leg in transplant patient"

https://info.visualdx.com/l/11412/2020-03-31/6h4hdz on 6/10/2021







#### Dermoscopy

- Leads to fewer biopsies needed to find a skin cancer
  - 4-5:1 with
    dermoscopy vs
    12-15:1 with
    naked eye alone
- Detects skin cancers at an earlier stage







Fig 4. Dermoscopic images showing dermoscopic features associated with different basal cell subtypes. A. Superficial basal cell carcinoma presenting with an erosion (asterisk), serpentine vessels (arrowhead), and leaf-like areas (arrow). B. Nodular basal cell carcinoma presenting with an ulcer (asterisk), arborizing vessels (arrowhead), and blue ovoid nests (arrow).

Table III. Dermoscopic structures associated with basal cell carcinoma subtypes



Multiple small erosions



Serpentine vessels



Leaflike structures



on-superficial basal Blue ovoid nest cell carcinoma<sup>60</sup>



Arborizing vessels



Ulceration

HEALTH



HAWAP

HEALTH

PARTNERS

Yelamos O, Usefulness of dermoscopy to improve the clinical and histologic diagnosis of skin cancers JAAD 2019, 365-377 PACIFIC



#### Dermoscopy




Fig 3. A, Macroscopic picture of a superficial spreading malignant melanoma (Breslow thickness 0.52 mm; Clark level II). B, Dermoscopy of A shows (atypical) pigment network and branched streaks and can therefore be considered a melanocytic lesion.





Fig 6. A, Macroscopic picture of a seborrheic keratosis. B, Dermoscopy of A shows comedolike openings and multiple milia-like cysts.

Braun RP Dermoscopy of pigmented skin lesions JAAD 2005; 52:109-21




#### **Biopsy Techniques: Shave and Saucerization**

- Shave biopsy
  - Commonly used for diagnosis of lesions with superficial pathology such as BCC/SCC in situ
- Saucerization
  - Can be considered for small melanocytic lesions to below anticipated plane of lesion



### **Biopsy Techniques: Punch**

- Commonly used for diagnosis of rashes or complete removal of small solitary lesions
- Partial sampling may limit evaluation of melanocytic lesions
  - Histologic Symmetry of entire lesion
  - Heterogenous lesions (such as melanoma arising in a nevus)
  - Accurate tumor staging and treatment if biopsy does not capture deepest component of melanoma





## **Biopsy techniques**

- Incisional biopsy
  - Considered when
    - Low clinical suspicion
    - Lesion is too large to completely excise
    - Concern for cosmesis
- Excisional biopsy
  - Preferred biopsy technique for clinically-suspected melanoma
    - Pathologist can examine lesion in entirety
    - Accurate Breslow depth



Η Δ\Λ/ΔΓ

PARTNERS

## WHO

#### Who is at risk?

#### HAWAI'I PACIFIC HEALTH

HAWAI'I HEALTH PARTNERS

## **Risk Factors for NMSC**

#### Environmental

- Cumulative sun exposure/occupational (SCC)
- Intermittent sun exposure/recreational (BCC)
- Ionizing radiation (BCC/SCC)
- HPV (SCC)
- Cigarette smoking (SCC)
- Pigmentary phenotype
  - Fair skin, "always burns, never tans"
  - Freckling, red hair (SCC/BCC)



## **Risk Factors for NMSC**

#### Genetic syndromes

- Xeroderma pigmentosum (XP)
- Oculocutaneous albinism
- Epidermodysplasica verruciformis
- Dystrophic epidermolysis bullosa
- Ferguson-Smith syndrome
- Muir-Torre syndrome
- Nevoid basal cell carcinoma syndrome
- Bazex Rombo syndrome

#### Predisposing clinical setting

- Chronic non-healing wounds
- Longstanding discoid lupus erythematosus, erosive lichen planus or lichen sclerosus
- Porokeratosis
- Immunosuppression: Organ transplantation, CLL, AIDS
- Prior history of skin cancer



### **Risk Factors for Melanoma**

- More than 50 moles, large moles or atypical (unusual) nevi
- A blood relative (parent, sibling, child, aunt, uncle, cousin) who has had melanoma
- Sun-sensitive skin (i.e., tendency to sunburn easily, red or blond hair, or blue or green eyes)
- A history of excessive sun exposure (including sunburns) or indoor tanning
- A history of other cancers, such as breast or thyroid cancer (CDKN2A/BRCA2)
- Individuals who have been diagnosed with either BCC or SCC have an increased risk of developing future skin cancers, including melanoma
- Melanoma survivors have an approximately nine-fold increased risk of developing another melanoma compared to the general population



### Melanoma in patients with skin of color

- Patients with skin of color are often diagnosed with skin cancer in later stages when it's more difficult to treat
- Research has shown that patients with skin of color are less likely than Caucasian patients to survive melanoma, the deadliest form of skin cancer
- Patients with skin of color are prone to skin cancer in areas that aren't commonly exposed to the sun, like the palms of the hands, the soles of the feet, the groin, and the inside of the mouth

(1) Agbai ON, Buster K, Sanchez M, Hernandez C, Kundu RV, Chiu M, Roberts WE, Draelos ZD, Bhushan R, Taylor SC, Lim HW. Skin cancer and photoprotection in people of color: a review and recommendations for physicians and the public. J Am Acad Dermatol. 2014;70(4):748-62.

(2) Dawes SM et al. Racial disparities in melanoma survival. J Am Acad Dermatol. 2016 Nov; 75(5):983-991

(3) Agbai ON, Buster K, Sanchez M, Hernandez C, Kundu RV, Chiu M, Roberts WE, Draelos ZD, Bhushan R, Taylor SC, Lim HW. Skin cancer and photoprotection in people of color: a review and recommendations for physicians and the public. J Am Acad Dermatol. 2014;70(4):748-62.



## How?

#### How can we prevent skin cancers?

#### HAWAI'I PACIFIC HEALTH PARTNERS

40

### Photoprotection

- Seek shade when outdoors
- Wear photoprotective clothing, including wide-brimmed hats and sunglasses
- Generously apply broad-spectrum, water-resistant sunscreen with an SPF of 30 or higher on exposed areas
- Furthermore, those concerned about the potential environmental impact of chemical sunscreen ingredients can use mineral (also known as physical or inorganic) sunscreens containing zinc oxide or titanium dioxide





### **Topical and Oral Prophylaxis for SCC**

- 5%-Fluorouracil (5FU): 75% reduction in SCC
- 5-FU with calcipotriol (faster treatment)
- Oral prophylaxis: Nicotinamide 500 mg BID
  - OTC, no known major side-effects
  - 30% reduction in SCC
- Oral Acitretin
  - Decreased SCC formation by 54%



### **Take Home Points**

- Anybody can detect skin cancer
- If it's growing, bleeding, painful, or an "ugly duckling", get it checked out
  - (When in doubt, get it checked out)
- Prevention and early treatment is Key



#### HAWAI'I PACIFIC HEALTH

HAWAI'I HEALTH PARTNERS



## HHP/HPH Community Webinar Series

## Thursday, June 17, 2021 5:30pm – 6:30 pm

\*Agenda is tentative and is subject to change



## Thank you!

- A recording of the meeting will be available afterwards.
- Unanswered question?
  - Contact us at info@hawaiihealthpartners.org

#### HAWAI'I PACIFIC HEALTH

HAWAI'I HEALTH PARTNERS